Artificial Intelligence
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Today's issue
Refine Search
Biotechnology
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Biotechnology
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Pharmaceutical
Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, today announced a research collaboration with US pharma major Eli Lilly to develop genetic medicine therapeutics. 6 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Biotechnology
US AI-enabled biotech Recursion and UK-based Exscientia today announced the companies have entered into a definitive merger agreement. 8 August 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
California’s ReviR Therapeutics has completed a $30 million series A financing round, bringing its total funding to $54 million. 29 July 2024
Pharmaceutical
Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA. 18 July 2024
Biotechnology
AI-focused start-up Formation Bio has raised $372 million in a series D financing. 27 June 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
Oxford, UK-based start-up Ochre Bio has announced the start of a multi-year data licence agreement with British pharma major GSK. 13 June 2024
Biotechnology
Vilya, a biotechnology company focused on designing novel medicines, has announced a $71 million expansion of its series A financing. 5 June 2024
Biotechnology
Israel-based artificial intelligence (AI) focused biotech Biolojic Design has entered into a multi-target drug discovery collaboration with Germany’s Merck KGaA. 4 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Biotechnology
AI-driven precision medicine company Exscientia has announced a headcount reduction of between 20% and 25%. 22 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Biotechnology
Cambridge, USA-based generative protein design pioneer Nabla Bio has announced the closure of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors. 20 May 2024
Biotechnology
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Biotechnology
Californian companies Gilead Sciences and Genesis Therapeutics have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets. 10 September 2024
Biotechnology
Danish clinical-stage techbio firm Evaxion Biotech, which is developing AI-Immunology powered vaccines, announced new clinical Phase II data for its lead compound EVX-01. 9 September 2024
Biotechnology
ZipBio, a newly launched start-up based in Seattle, USA, is aiming to set a new standard in the development of biologics and gene therapies by utilizing generative AI technology. 9 September 2024
Pharmaceutical
Genetic Leap, an AI-native techbio company innovating at the cutting edge of Artificial Intelligence and RNA genetic medicine, today announced a research collaboration with US pharma major Eli Lilly to develop genetic medicine therapeutics. 6 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Biotechnology
US AI-enabled biotech Recursion and UK-based Exscientia today announced the companies have entered into a definitive merger agreement. 8 August 2024
Pharmaceutical
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Pharmaceutical
California’s ReviR Therapeutics has completed a $30 million series A financing round, bringing its total funding to $54 million. 29 July 2024
Pharmaceutical
Boehringer Ingelheim has entered partnership with AI company Brainomix for a collaborative program of activity to improve the care of patients with fibrosing lung disease in the USA. 18 July 2024
Biotechnology
AI-focused start-up Formation Bio has raised $372 million in a series D financing. 27 June 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
Oxford, UK-based start-up Ochre Bio has announced the start of a multi-year data licence agreement with British pharma major GSK. 13 June 2024
Biotechnology
Vilya, a biotechnology company focused on designing novel medicines, has announced a $71 million expansion of its series A financing. 5 June 2024
Biotechnology
Israel-based artificial intelligence (AI) focused biotech Biolojic Design has entered into a multi-target drug discovery collaboration with Germany’s Merck KGaA. 4 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Biotechnology
AI-driven precision medicine company Exscientia has announced a headcount reduction of between 20% and 25%. 22 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Biotechnology
Cambridge, USA-based generative protein design pioneer Nabla Bio has announced the closure of a $26 million Series A financing, led by Radical Ventures with participation from all existing investors. 20 May 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze